TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Race Oncology Ltd announced that all resolutions at its Annual General Meeting were passed, reflecting strong shareholder support. This outcome may bolster the company’s strategic initiatives in advancing its clinical programs and exploring partnerships, potentially impacting its market position positively.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is a biopharmaceutical company focused on cancer care, listed on the Australian Securities Exchange. Their lead product, RCDS1, is an anticancer agent targeting cancer growth regulators, with ongoing clinical programs in various oncology indications. The company collaborates with several institutions and is exploring partnerships to enhance patient access to their treatments.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
See more data about RAC stock on TipRanks’ Stock Analysis page.